Scarica l'app Stockscreener
8.85
0.45%
0.04
Precedente Chiudi:
$8.81
Aprire:
$8.91
Volume 24 ore:
2.13M
Relative Volume:
1.17
Capitalizzazione di mercato:
$874.81M
Reddito:
-
Utile/perdita netta:
$-44.84M
Rapporto P/E:
-18.83
EPS:
-0.47
Flusso di cassa netto:
$-44.23M
1 W Prestazione:
-11.76%
1M Prestazione:
-21.75%
6M Prestazione:
-44.06%
1 anno Prestazione:
-25.76%
Intervallo 1D:
$8.61
$9.18
Intervallo di 1 settimana:
$8.61
$10.11
Portata 52W:
$6.66
$18.90
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Nome
Ars Pharmaceuticals Inc
Settore
Industria
Telefono
858-771-9307
Indirizzo
11682 EL CAMINO REAL, SUITE 300, SAN DIEGO
Compare SPRY vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
8.85 | 870.86M | 0 | -44.84M | -44.23M | -0.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-04 | Ripresa | Roth Capital | Buy |
| 2025-09-04 | Iniziato | Roth Capital | Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-10 | Iniziato | Oppenheimer | Outperform |
| 2024-08-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-08-13 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | Reiterato | Leerink Partners | Outperform |
| 2024-07-25 | Iniziato | Raymond James | Outperform |
| 2024-03-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | Iniziato | Wedbush | Outperform |
| 2023-01-03 | Iniziato | William Blair | Outperform |
| 2022-12-13 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Ars Pharmaceuticals Inc Borsa (SPRY) Ultime notizie
Is ARS Pharmaceuticals Inc. stock vulnerable to regulatory risksSwing Trade & Weekly High Return Opportunities - mfd.ru
ARS Pharmaceuticals: Climbing Neffy Sales And Global Expansion Could Re-Rate The Stock - Seeking Alpha
Why hedge funds are buying ARS Pharmaceuticals Inc. stockJuly 2025 Reactions & High Win Rate Trade Alerts - mfd.ru
ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® at 2026 American Academy of Allergy, Asthma and Immunology Annual Scientific Meeting - Investing News Network
Needle-free epinephrine nasal spray may cut costs and boost patient preference - Stock Titan
ARS Pharmaceuticals (SPRY) Stock Price, News & Analysis $SPRY - MarketBeat
Market Moves: Is INHDs ROE strong enoughWeekly Trend Summary & Precise Trade Entry Recommendations - baoquankhu1.vn
(SPRY) and the Role of Price-Sensitive Allocations - Stock Traders Daily
SPRY SEC FilingsARS Pharms 10-K, 10-Q, 8-K Forms - Stock Titan
Will ARS Pharmaceuticals Inc. stock recover after earningsWeekly Loss Report & Capital Efficiency Focused Ideas - mfd.ru
How Investors May Respond To ARS Pharmaceuticals (SPRY) Expanding EURneffy Pediatric Use Across Europe - Yahoo Finance
Aquestive leaps, despite receiving CRL for Anaphylm NDA - The Pharma Letter
ARS Pharma Gets Positive CHMP Opinion For 1 Mg EURneffy Nasal Spray - Nasdaq
Needle-free allergy rescue for kids wins key EU support - Stock Titan
US FDA declines to approve Aquestive's oral drug for allergic reactions - Reuters
Targets Report: Will OceanPal Inc benefit from geopolitical trendsCPI Data & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Lisanti Capital Growth LLC Sells 208,886 Shares of ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
Weekly Recap: Will ARS Pharmaceuticals Inc announce a stock splitJuly 2025 Outlook & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
ARS Pharmaceuticals (NASDAQ:SPRY) Cut to Strong Sell at Zacks Research - MarketBeat
Repeat Offenders: Neffy, Anktiva Promotions Draw Another US FDA Untitled Letter After Crackdown - Citeline News & Insights
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Responsive Playbooks and the SPRY Inflection - Stock Traders Daily
Update Recap: Will ARS Pharmaceuticals Inc stock recover after earningsJuly 2025 Snapshot & Capital Efficient Trade Techniques - baoquankhu1.vn
Pullback Watch: Will ARS Pharmaceuticals Inc stock recover after earnings2025 Top Gainers & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
ARS Pharmaceuticals Reports Q3 2025 Financial Results - MSN
What ARS Pharmaceuticals (SPRY)'s neffyinSchools California Expansion Means For Shareholders - Sahm
Valuation Update: Is ARS Pharmaceuticals Inc a top pick in the sectorInsider Selling & Free High Return Stock Watch Alerts - baoquankhu1.vn
Aug Rallies: Can ARS Pharmaceuticals Inc generate free cash flowJuly 2025 Snapshot & AI Powered Market Entry Ideas - baoquankhu1.vn
Pullback Watch: Is ARS Pharmaceuticals Inc attractive at current valuationJuly 2025 Action & Weekly Consistent Profit Watchlists - baoquankhu1.vn
What are ARS Pharmaceuticals Inc.’s earnings expectationsTrade Exit Report & Reliable Breakout Forecasts - mfd.ru
California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free ... - nrtoday.com
California K-12 Schools Now Eligible for neffyinSchools - GlobeNewswire
ARS Pharmaceuticals, Inc. (SPRY) Investor Outlook: Analyzing the 171% Upside Potential for This Biotech Stock - DirectorsTalk Interviews
Assessing ARS Pharmaceuticals (SPRY) Valuation After China Community Approval For Neffy Epinephrine Spray - simplywall.st
Understanding the Setup: (SPRY) and Scalable Risk - Stock Traders Daily
Is ARS Pharmaceuticals Inc a top pick in the sector2025 Fundamental Recap & Risk Controlled Daily Plans - baoquankhu1.vn
Sell Signal: Is ARS Pharmaceuticals Inc stock a falling knife or bargain buy2025 Historical Comparison & Weekly High Return Stock Forecasts - baoquankhu1.vn
Targets Report: What analysts say about ARS Pharmaceuticals Inc stock2025 Performance Recap & Breakout Confirmation Trade Signals - baoquankhu1.vn
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 12.3%Should You Sell? - MarketBeat
Assessing ARS Pharmaceuticals (SPRY) Valuation After A 19.3% Single Day Share Price Jump - Yahoo Finance
There's No Escaping ARS Pharmaceuticals, Inc.'s (NASDAQ:SPRY) Muted Revenues Despite A 25% Share Price Rise - 富途牛牛
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Catapults 25% Though Its Price And Business Still Lag The Industry - simplywall.st
ARS Pharma (SPRY) Gains China Approval for Neffy, Roth Reiterates Buy Rating - Finviz
What's Going On With ARS Pharmaceuticals Stock Friday?ARS Pharmaceuticals (NASDAQ:SPRY) - Benzinga
Bad News For Competitor Turns Into Big Win For ARS Pharma Stock - Sahm
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap UpShould You Buy? - MarketBeat
Assessing ARS Pharmaceuticals (SPRY) Valuation After China Approval Expands Neffy Allergy Market Reach - Sahm
12 Stocks that Will Bounce Back According to Wall Street Analysts - Insider Monkey
What drives ARS Pharmaceuticals Inc stock priceVolatility Index Analysis & Access High Yield Alerts - earlytimes.in
ARS Pharmaceuticals, Inc.Common Stock (NQ: SPRY - FinancialContent
ARS Pharmaceuticals, Inc. (SPRY): Investor Outlook Reveals a Compelling 162% Upside Potential - DirectorsTalk Interviews
Ars Pharmaceuticals Inc Azioni (SPRY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):